LAPC

FibroGen to Report First Quarter 2022 Financial Results

Retrieved on: 
Montag, April 25, 2022
MDS, Idiopathic pulmonary fibrosis, Microdeletion syndrome, Duchenne muscular dystrophy, Chronic kidney disease, CTGF, NASDAQ, Research, Pancreatic cancer, Interest, LAPC, Duchenne, Anemia, GLOBE, CIA, HIF, DMD, SAN, Company, Webcast, CKD, Biology, IPF, Therapy, Pharmaceutical industry

SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close.

Key Points: 
  • SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close.
  • FibroGen will also conduct a conference call on that day at 5:00 p.m.
  • ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
  • Interested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events .

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

Retrieved on: 
Mittwoch, April 20, 2022
Microdeletion syndrome, U.S. Securities and Exchange Commission, Security (finance), Risk, NASDAQ, Research, Diagnosis, CTGF, GLOBE, HIF, Patient, Life expectancy, United Nations Department of Economic and Social Affairs, Idiopathic pulmonary fibrosis, Symptoms of COVID-19, Weight loss, Annual report, Duchenne, Food, Incidence, Anemia, CIA, HRCT, AM, Mortality, Vital capacity, Company, Biology, IPF, Disease, Pamrevlumab, Fatigue, MDS, Awareness, Marketing, Duchenne muscular dystrophy, Chronic kidney disease, Pancreatic cancer, LAPC, DMD, Walking, Failure, Weakness, SEC, CKD, Safety, Fast Track, Prevalence, Therapy, ODD, Cough, FVC, SAN, M.D, Method, Organ dysfunction, Orphan, Oxygen, Scar, Cancer, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for ZEPHYRUS-1, the first of two Phase 3 clinical studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease.

Key Points: 
  • SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc.(NASDAQ: FGEN) today announced completion of patient enrollment for ZEPHYRUS-1, the first of two Phase 3 clinical studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease.
  • The Phase 3 clinical development program for pamrevlumab for IPF consists of two studies, ZEPHYRUS-1 and ZEPHYRUS-2.
  • These trials are randomized, double-blind, placebo-controlled, multi-center Phase 3 trials designed to evaluate the efficacy and safety of pamrevlumab in patients with IPF.
  • Pamrevlumab has demonstrated a safety and tolerability profile that has supported ongoing clinical investigation in IPF, LAPC, and DMD.

RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride Event to End Pancreatic Cancer

Retrieved on: 
Dienstag, April 19, 2022
Oncology, Philanthropy, Health, Fund Raising, General Health, Pharmaceutical, Biotechnology, CEO, Awareness, Technology, Cholangiocarcinoma, Pancreatic Cancer Action Network, Pancreatic cancer, Pancreas, LAPC, CA, Â, Patient, Movement, Volunteering, Neoplasm, Safety, Silicon, FDA, Disease, Cancer, Pharmaceutical industry

RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, announced today it will join the Pancreatic Cancer Action Network (PanCAN) as a Silver Sponsor of the organizations PurpleStride Silicon Valley event to end pancreatic cancer.

Key Points: 
  • RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, announced today it will join the Pancreatic Cancer Action Network (PanCAN) as a Silver Sponsor of the organizations PurpleStride Silicon Valley event to end pancreatic cancer.
  • All of us at RenovoRx proudly support the PurpleStride walk, which improves pancreatic cancer awareness across the country, said Shaun Bagai, CEO of RenovoRx.
  • RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.
  • The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients.

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

Retrieved on: 
Mittwoch, April 13, 2022
Oncology, Health, Diabetes, Radiology, Clinical Trials, Pharmaceutical, Biotechnology, Clinical trial, Syringe, Biotechnology, Medpace, U.S. Securities and Exchange Commission, IND, NASDAQ, PMCB, Pancreatic cancer, LAPC, Private Securities Litigation Reform Act, Diabetes, Capsule, Catalent, Angiography, Form 10-K, Neoplasm, Ifosfamide, Technology, Form, Contract, Insulin, Contract research organization, Immortalised cell line, FDA, Liver, Cell, Cancer, Pharmaceutical industry, Medical device, Medical imaging

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has decided to accelerate preparations for the start of its Phase 2b clinical trial in locally advanced, inoperable pancreatic (LAPC) using its CypCapsTM clinical trial product.

Key Points: 
  • PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that PharmaCyte has decided to accelerate preparations for the start of its Phase 2b clinical trial in locally advanced, inoperable pancreatic (LAPC) using its CypCapsTM clinical trial product.
  • Previously, our plan was to begin the work to commence a clinical trial in LAPC after the FDA lifted the clinical hold.
  • PharmaCyte will also need to reengage with Medpace, the Contract Research Organization that PharmaCyte has selected to conduct its proposed clinical trial.
  • Clinical trial syringes containing CypCaps will need to be manufactured and delivered to Catalents locations throughout the U.S. for storage and distribution for the clinical trial.

AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

Retrieved on: 
Dienstag, April 12, 2022
Manuscript, Cancer, Clinical trial, Pancreatic cancer, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Food, LAPC, Inspectorate, Private Securities Litigation Reform Act, GLOBE, Program, Patient, University of Nebraska Medical Center, Lists of diseases, UNMC, Innovation, Company, Degenerative disease, Immune system, American, Erasmus MC, CRO, NYSE, Nebraska Medicine, FOLFIRINOX, Safety, AIM, FDA, PSLRA, Disease, University, Therapy, Survival, Pharmaceutical industry, Rintatolimod

OCALA, Fla., April 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today provided an update on its development program evaluating Ampligen® for the treatment of pancreatic cancer.

Key Points: 
  • Additionally, Ampligen has shown success in increasing survival rates and efficacy in the treatment of animal tumors when used in combination with checkpoint blockade therapies.
  • Ampligen is also being used as a monotherapy to treat pancreatic cancer patients in a named patient program approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center.
  • We continue to be encouraged by the progress and data demonstrated by Ampligen for the treatment of pancreatic cancer.
  • Additionally, we continue to amass an encouraging growing body of data that supports our belief in Ampligen to offer an important treatment option to patients living with pancreatic cancer.

RenovoRx Reports Full Year 2021 Financial Results

Retrieved on: 
Mittwoch, März 30, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Directors and officers liability insurance, Company, Cancer, NASDAQ, Patent, Cholangiocarcinoma, Forward-looking statement, Officer, Nasdaq, Survival, Micro, Research, Hospital, CEO, U.S. Securities and Exchange Commission, Neoplasm, Quality of life, Industry, Safety, Securities Exchange Act of 1934, Securities Act of 1933, COVID-19, Intellectual property, Columbia, Drug Quality and Security Act, Nature, FDA, Technology, Terminology, IPO, Pancreatic cancer, Insurance, Patient, Security (finance), Pharmaceutical industry, Medical imaging, EU, LAPC, THE PHASE 3 TIGER-PAC CLINICAL TRIAL, RENOVORX, INC.

RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the year ended December 31, 2021.

Key Points: 
  • RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the year ended December 31, 2021.
  • We successfully closed on our initial public offering and listed on the NASDAQ under RNXT, said Shaun Bagai, CEO of RenovoRx.
  • RenovoRx is addressing this problem by localizing therapy to treat tumors via our proprietary RenovoTAMP (RenovoRx Trans-Arterial Micro-Perfusion) therapeutic platform.
  • Financial Highlights for the Fiscal Year Ended December 31, 2021
    Cash and cash equivalents as of December 31, 2021, were $15.2 million.

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

Retrieved on: 
Mittwoch, März 16, 2022
Oncology, Health, Diabetes, Genetics, Pharmaceutical, Biotechnology, HEK293, U.S. Securities and Exchange Commission, Program, Technology, Cell, Ifosfamide, FDIC, Private Securities Litigation Reform Act, Capsule, FDA, Form, Cytochrome, Cytochrome P450, Diabetes, Immortalised cell line, NASDAQ, Neoplasm, IND, Form 10-K, Clinical trial, Insulin, Pancreatic cancer, Food, Liver, Company, Research, Cancer, Ascites, Biotechnology, R, Catheter, Vii, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LAPC, PMCB, Pharmaceutical industry, Online gambling, Medical device, Medical imaging

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the financial and operational results for its third quarter ended January 31, 2022, and provided an overview of recent operational highlights (PharmaCytes Fiscal Year begins May 1 and ends April 30).

Key Points: 
  • PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the financial and operational results for its third quarter ended January 31, 2022, and provided an overview of recent operational highlights (PharmaCytes Fiscal Year begins May 1 and ends April 30).
  • Cash Position: PharmaCyte had approximately $87 million in cash on hand as of January 31, 2022.
  • In November 2021, PharmaCyte announced that the empty capsule material that makes up its CypCaps pancreatic cancer product does not cause skin irritation.
  • In December 2021, PharmaCyte successfully completed the 36-month time point in its ongoing Master Cell Bank stability study.

RenovoRx to Participate in March 2022 Investor Conferences

Retrieved on: 
Freitag, März 11, 2022
Oncology, Medical Devices, Health, FDA, Pharmaceutical, Biotechnology, Safety, LAPC, FDA, Cancer, Technology, Cholangiocarcinoma, Pancreatic cancer, CA, Neoplasm, CEO, Pharmaceutical industry

RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leaderships participation in two upcoming Investor Conferences this month.

Key Points: 
  • RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leaderships participation in two upcoming Investor Conferences this month.
  • Webcast: A link to this panel will be posted to the RenovoRx Website Events page when it becomes available.
  • RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform.
  • RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards Life Sciences Edition 2020 for its RenovoTAMP technology.

Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates

Retrieved on: 
Donnerstag, März 10, 2022
Nasdaq, Mucositis, Head, Safety, Incidence, Large-cell lung carcinoma, LAPC, Private Securities Litigation Reform Act, Company, Therapy, Survival, FDA, Failure, Annual report, GC4419, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, U.S. Securities and Exchange Commission, Research, Investment, AESOP, NDA, Lung cancer, HNC, Health, Hand, Privacy, GLOBE, Patient, Radiation, SOM, COVID-19, Pancreatic cancer, Ownership, SBRT, Esophagitis, SEC, Food, Insurance, CEO, NSCLC, New Drug Application, Pharmaceutical industry, Airline

MALVERN, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided recent corporate updates.

Key Points: 
  • The Company had previously announced topline results from the ROMAN trial on October 19, 2021.
  • Research and development expenses were $9.2 million in the fourth quarter of 2021, compared to $14.6 million for the same period in 2020.
  • General and administrative expenses were $5.3 million in the fourth quarter of 2021, compared to $4.3 million for the same period in 2020.
  • As of December 31, 2021, Galera had cash, cash equivalents and short-term investments of $71.2 million.

AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer

Retrieved on: 
Dienstag, März 8, 2022
Safety, Cancer, Clinical trial, Erasmus, Nebraska Medicine, University, LAPC, Flow cytometry, Private Securities Litigation Reform Act, Patient, Company, AIM, Research, Manuscript, Therapy, Oncology, Survival, FDA, Hope, University of Nebraska Medical Center, Neutrophil, American, Innovation, Degenerative disease, MD, Lists of diseases, Myelocyte, CT, FOLFIRINOX, NYSE, UNMC, GLOBE, Systemic, NLR, PFS, Doctor of Philosophy, RECIST, Pancreatic cancer, Erasmus MC, PSLRA, Progression-free survival, CT scan, COVID-19, Survivor, Disease, Recurrence, Program, Pharmaceutical industry, Vaccine, Rintatolimod

OCALA, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the publication of positive data from a single-center named patient program treating advanced and metastatic pancreatic cancer patients. The manuscript titled, “Rintatolimod (Ampligen®) enhances numbers of peripheral B cells and is associated with longer survival in patients with locally advanced and metastasized pancreatic cancer pre-treated with FOLFIRINOX: a single-center named patient program1,” was published in the peer-reviewed journal, Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer.

Key Points: 
  • We are very encouraged by these data, which we believe reaffirm the potential of Ampligen to offer an important treatment option to patients living with pancreatic cancer.
  • These data now in hand play a key role in the overall advancement of our pancreatic cancer program and provide valuable insight as we continue to execute the path forward.
  • The Company plans to conduct a Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer.
  • However, we have been corresponding with the FDA and we anticipate, but cannot assure, that the hold will be lifted.